WST
Income statement / Annual
Last year (2024), West Pharmaceutical Services, Inc.'s total revenue was $2.89 B,
a decrease of 1.92% from the previous year.
In 2024, West Pharmaceutical Services, Inc.'s net income was $492.70 M.
See West Pharmaceutical Services, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.89 B |
$2.95 B |
$2.89 B |
$2.83 B |
$2.15 B |
$1.84 B |
$1.72 B |
$1.60 B |
$1.51 B |
$1.40 B |
| Cost of Revenue |
$1.89 B
|
$1.82 B
|
$1.75 B
|
$1.66 B
|
$1.38 B
|
$1.23 B
|
$1.17 B
|
$1.09 B
|
$1.01 B
|
$944.00 M
|
| Gross Profit |
$998.50 M
|
$1.13 B
|
$1.14 B
|
$1.18 B
|
$767.80 M
|
$605.70 M
|
$545.40 M
|
$512.60 M
|
$501.10 M
|
$455.80 M
|
| Gross Profit Ratio |
0.35
|
0.38
|
0.39
|
0.42
|
0.36
|
0.33
|
0.32
|
0.32
|
0.33
|
0.33
|
| Research and Development Expenses |
$69.10 M
|
$68.40 M
|
$58.50 M
|
$52.80 M
|
$46.90 M
|
$38.90 M
|
$40.30 M
|
$39.10 M
|
$36.80 M
|
$34.10 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$262.90 M
|
$242.60 M
|
$239.80 M
|
$233.00 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$338.50 M
|
$353.40 M
|
$316.90 M
|
$362.80 M
|
$302.00 M
|
$272.70 M
|
$262.90 M
|
$242.60 M
|
$239.80 M
|
$233.00 M
|
| Other Expenses |
$21.00 M
|
$31.50 M
|
$26.80 M
|
$7.90 M
|
$12.00 M
|
$2.40 M
|
$4.80 M
|
-$2.00 M
|
-$27.70 M
|
-$60.10 M
|
| Operating Expenses |
$428.60 M
|
$454.00 M
|
$402.20 M
|
$423.50 M
|
$360.90 M
|
$311.60 M
|
$303.20 M
|
$281.70 M
|
$276.60 M
|
$267.10 M
|
| Cost And Expenses |
$2.32 B
|
$2.27 B
|
$2.15 B
|
$2.08 B
|
$1.74 B
|
$1.55 B
|
$1.48 B
|
$1.37 B
|
$1.28 B
|
$1.21 B
|
| Interest Income |
$19.60 M
|
$28.00 M
|
$5.10 M
|
$1.00 M
|
$1.40 M
|
$3.80 M
|
$2.10 M
|
$1.30 M
|
$1.10 M
|
$1.60 M
|
| Interest Expense |
$3.00 M
|
$9.00 M
|
$7.90 M
|
$7.20 M
|
$6.80 M
|
$4.70 M
|
$6.30 M
|
$6.50 M
|
$7.00 M
|
$12.50 M
|
| Depreciation & Amortization |
$155.40 M
|
$137.30 M
|
$120.60 M
|
$122.30 M
|
$109.10 M
|
$103.40 M
|
$104.40 M
|
$96.70 M
|
$90.70 M
|
$89.90 M
|
| EBITDA |
$743.90 M |
$844.10 M |
$887.90 M |
$895.20 M |
$531.70 M |
$399.40 M |
$355.30 M |
$335.90 M |
$319.60 M |
$220.00 M |
| EBITDA Ratio |
0.26
|
0.29
|
0.3
|
0.31
|
0.24
|
0.22
|
0.14
|
0.14
|
0.13
|
0.09
|
| Operating Income Ratio |
0.2
|
0.23
|
0.25
|
0.27
|
0.19
|
0.16
|
0.14
|
0.14
|
0.13
|
0.09
|
| Total Other Income/Expenses Net |
$15.60 M
|
$22.00 M
|
-$54.10 M
|
-$3.40 M
|
-$5.60 M
|
-$4.80 M
|
$400,000.00
|
-$3.40 M
|
-$5.40 M
|
-$12.50 M
|
| Income Before Tax |
$585.50 M
|
$698.00 M
|
$679.90 M
|
$748.90 M
|
$401.30 M
|
$291.80 M
|
$240.70 M
|
$222.40 M
|
$189.80 M
|
$116.10 M
|
| Income Before Tax Ratio |
0.2
|
0.24
|
0.24
|
0.26
|
0.19
|
0.16
|
0.14
|
0.14
|
0.13
|
0.08
|
| Income Tax Expense |
$107.50 M
|
$122.30 M
|
$114.70 M
|
$107.20 M
|
$72.50 M
|
$59.00 M
|
$41.40 M
|
$80.90 M
|
$54.40 M
|
$26.30 M
|
| Net Income |
$492.70 M
|
$593.40 M
|
$585.90 M
|
$661.80 M
|
$346.20 M
|
$241.70 M
|
$206.90 M
|
$150.70 M
|
$143.60 M
|
$95.60 M
|
| Net Income Ratio |
0.17
|
0.2
|
0.2
|
0.23
|
0.16
|
0.13
|
0.12
|
0.09
|
0.1
|
0.07
|
| EPS |
6.75 |
7.99 |
7.88 |
8.9 |
4.68 |
3.27 |
2.8 |
2.04 |
1.96 |
1.33 |
| EPS Diluted |
6.69 |
7.88 |
7.73 |
8.67 |
4.57 |
3.21 |
2.74 |
1.99 |
1.91 |
1.3 |
| Weighted Average Shares Out |
$73.00 M
|
$74.30 M
|
$74.40 M
|
$74.40 M
|
$73.90 M
|
$74.00 M
|
$73.90 M
|
$73.90 M
|
$73.30 M
|
$72.00 M
|
| Weighted Average Shares Out Diluted |
$73.70 M
|
$75.30 M
|
$75.80 M
|
$76.30 M
|
$75.80 M
|
$75.40 M
|
$75.40 M
|
$75.80 M
|
$75.00 M
|
$73.80 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
